Soligenix halts Phase 3 trial of HyBryte for lymphoma treatment

April 28, 2026 7:30 AM

Soligenix Inc. (NASDAQ: SNGX) announced that its Phase 3 FLASH2 trial evaluating HyBryte for cutaneous T-cell lymphoma treatment was halted ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found